Dupilumab (anti-IL4/13) is one biologic that has been approved for AD, and more recently, tralokinumb (anti-IL13), lebrikizumab (anti-IL4/13), abrocitinib and upadacitinib [Janus kinases (JAKs) inhibitors], have been added (6, 7). The gene discussed is IL4; the disease is Alzheimer disease.